- <sup>1</sup>A comparative study of multidrug resistant bacteria (MDRB) isolated from various patients in
- 2 different wards of a hospital during post Covid-19
- 3
- 4 Abhishek Ojha<sup>1 $\Box$ </sup>, Dwight Figueiredo<sup>1</sup>, Shabnum Khan<sup>1</sup>
- $1$  Symbiosis Institute of Health Sciences, Symbiosis International (Deemed University),
- <sup>6</sup>Lavale (Hill Base), Pune 412115, Maharashtra, India.
- \* <sup>7</sup>Corresponding author; Abhishek Ojha; Email: ab.ojha@gmail.com
- 8 Dwight Figueiredo; Email: drdwight@sihspune.org
- <sup>9</sup>Shabnum Khan; Email: 42khanshabnum@gmail.com

### <sup>11</sup>**Abstract**

<sup>12</sup>Antibacterial resistance is an alarming global concern and a public health challenge of the 13 twenty-first century for which effective systems are required to track and treat ABR. We 14 performed microbiological and antibiotic susceptibility testing on the samples to detect and <sup>15</sup>characterize Multidrug-Resistant Bacteria (MDRB) isolated from patients segregating MDRB <sup>16</sup>characteristics (types, prevalence and distribution of MDRB) based on time (i.e., during 17 versus post covid-19) and location (i.e., different wards of a tertiary care hospital). We 18 observed an increase of MDRB in 2022 as compared to 2021 and 2023. These MDRB had a <sup>19</sup>Shannon and Simpson index values of 1.138 to 1.508 and 0.643 to 0.775, respectively and an 20 observed evenness values of 0.780 to 1.042, which revealed the microbial diversity recovered <sup>21</sup>from the patient samples. In keeping with previous MDR studies, *Klebsiella*, *E*. *coli*, <sup>22</sup>*Citrobacter*, *Acinetobacter* and *Pseudomonas* were identified from the patient samples. <sup>23</sup>Moreover, compared to previous reports, the percentage of MDR-bacteria, i.e., *Klebsiella* (40

<sup>24</sup>%), *E*. *coli* (28 %), and *Citrobacter* (19 %), populations were higher in this study. We 25 observed that Gamma-proteobacteria were predominant across all the recovered samples, and 26 that *Acinetobacter* and *Klebsiella* isolated from the samples were 100 % resistant to twenty 27 and eleven antibiotics, respectively. Furthermore, the fatality rate was low compared with the 28 available reports suggesting possibilities for effective recovery if given rapid and tailored 29 treatment. Given the challenges faced by MDRB strains more surveillance and tracking is 30 needed to ensure effective and specifically targeted treatment strategies.

<sup>31</sup>**Keywords**: Multi-drug resistant, Microbes, Antimicrobial susceptibility testing, comorbid,

32 Covid-19, Healthcare.

### <sup>33</sup>**1. Introduction**

<sup>34</sup>Over the previous decades, it has been observed that antibiotic resistance is increasing to 35 precariously high levels all over the world as new mechanisms of resistance are looming and 36 spreading worldwide (Alós et al., 2015; Hernando-Amado et al., 2019). Widespread, non-37 specific, and uninterrupted use of antibacterial antibiotics in treating bacterial infections has <sup>38</sup>been well documented in fuelling resistance among the distinct elements of bacterial 39 populations (Klein et al., 2018; Carvalho et al., 2022). Due to the continuous need of <sup>40</sup>antibacterial substances active against resistant gram-negative microflora, gram-positive <sup>41</sup>multi drug resistant (MDR) pathogens have been overwhelmed by gram-negative bacterial 42 infections (Jones, 2001). Among gram-negative microflora, the commonest MDR microbes <sup>43</sup>identified in severe patients are *Pseudomonas aeruginosa*, *Stenotrophomonas maltophilia*, <sup>44</sup>*Acinetobacter* sp., *and Enterobacteriaceae*. *Staphylococcus aureus* (methicillin-resistant) and <sup>45</sup>*Enterococci* sp. (vancomycin-resistant) are the most common gram-positive isolated, 46 although their occurrence is falling (Jones, 2001; Boucher et al., 2009). Hospital-acquired 47 infections (HAIs) have been known for over a century as a critical clinical issue affecting

48 healthcare quality, and they are the primary source of unfavourable healthcare outcomes (Aly 49 et al., 2008; Memish and El-Saed, 2009; Nannini et al., 2009). The development of MDR <sup>50</sup>microbes (MDRM) in the patient has become a public health issue, emerging as a new 51 concern in many parts of the health system or hospitals (Jindal et al., 2015; Dogru et al., 52 2010; Teng et al., 2009; Aly et al., 2008). There is extensive use of antibiotics as a drug in 53 critical care units, which establishes a selection burden and stimulates the development of 54 MDRM (Teng et al., 2009; Aly et al., 2008). Further, an intensive care unit (ICU) patient is <sup>55</sup>known to have a high risk of infection due to their underlying health conditions, exposure to 56 various invasive devices, and weakened immunity (Dettenkofer et al., 2001; Ylipalosaari et 57 al., 2006). The HAI rate in general wards is lower than that of ICU-HAI (Weinstein, 1998). 58 The ICU-HAI has been associated with higher costs, morbidity, and mortality (Iskandar et al., <sup>59</sup>2021; Neidell et al., 2012; Montassier et al., 2013; Gastmeier et al., 2005). The objective of 60 this research was to investigate HAI in various (ICUs, neonatal ICU (NICU), outpatient 61 departments (OPD), male wards, female wards, pediatric wards, and medicine wards) <sup>62</sup>departments to reveal the MDR microbial community, the anti-microbial resistance 63 descriptions, including their effect on MDRM-related mortality and comorbidity.

# <sup>64</sup>**2. Materials and methods**

## <sup>65</sup>*2.1. Site of study and patients*

<sup>66</sup>The study was performed as single-centre retrospective research at a 900-bed hospital (the 67 Symbiosis University Hospital and Research Centre, SUHRC, Pune, Maharashtra, India), 68 providing quality healthcare to the Pune's surrounding rural and upcoming urban areas. High 69 patient numbers ensure extensive contact with the local community flows daily due to <sup>70</sup>subsidized healthcare facilities and treatment strategies provided. The hospital provides for 71 both inpatient and outpatient patient treatment services. The hospital possesses operation

72 theatres, ICUs, NICUs, Wards, OPDs. During Covid-19 (Coronavirus disease-2019), the <sup>73</sup>hospital ran with specialized wards assigned to Covid-19-positive patients. The standard 74 infection control measures (PPE, personal protective equipment) and sterilization protocols 75 (https://www.england.nhs.uk/national-infection-prevention-and-control-manual-nipcm-for-76 england/chapter-1-standard-infection-control-precautions-sicps/) were followed to prevent 77 cross-contamination and spread of Covid-19.

## <sup>78</sup>*2.2. Clinical data*

<sup>79</sup>A descriptive retrospective investigation of the occurrence of MDR bacteria in patients 80 treated at the hospital from January 2021 to April 2023, patients' samples were collected from 81 the different hospital departments as a part of routine testing or when infections were 82 suspected /presumed to be the cause underlying diseases (ICU, NICU, OPD, male ward, 83 female ward, paediatric ward, and medicine ward). Clinical data information relevant to this 84 study was collected and extracted from the departments mentioned above, patient medical 85 charts, infection control surveillance forms, and microbiology laboratory results. The clinical 86 data extracted also included - patient symptoms and comorbidities, neoplasm-related data and 87 its treatment, and most importantly, MDR related infectious microorganisms and their 88 resistance pattern (based on sensitivity to antibiotics, which are recorded data from <sup>89</sup>microbiology laboratory culture test blood culture, etc.) MDRs were determined by applying 90 the Centres for Disease Control and Prevention (CDC) parameters (Horan et al., 2008).

<sup>91</sup>*2.3. Bacterial identification and susceptibility testing* 

92 Microbial isolates were determined by applying the BD Phoenix Automated Microbiology <sup>93</sup>System (USA) and Kirby-Bauer disk diffusion technique (Clinical and Laboratory Standards 94 Institute, 2006.). The protocol detailed, by Caroll et al. (2006) and Hudzicki (2009), were 95 applied to identification and antimicrobial susceptibility tests. Microorganism cultures were

96 obtained from patient samples from different anatomical locations on the body. We examined 97 body fluids such as pus, urine, swabs (from the foot and near the colon), sputum, stool, BAL <sup>98</sup>(Bronchoalveolar lavage) fluid, and ET (Endotracheal Secretion) secretion to determine the <sup>99</sup>occurrence of antibiotic-resistant microbes or pathogens across the samples. The isolates <sup>100</sup>*Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Acinetobacter* sp., and <sup>101</sup>*Citrobacter* sp., were examined to be MDR. An infection at many sites in the same patient 102 was revealed as distinct infection events, except that an identical microbe was revealed 103 concurrently. The clinical outcomes were evaluated up to hospital discharge or patient death. 104 For the reasons of this study, patient death was determined concerning the HAIs/ or as non-<sup>105</sup>HAIs-associated in agreement with the professional (Medical) who endorsed the patient 106 death, including clinical chart data examined by three of the authors of this study.

## <sup>107</sup>*2.4. Statistical analysis*

108 Descriptive statistics were used for categorised variables and expressed in terms of per cent <sup>109</sup>frequency. The normal distribution and diversity (alpha and beta) index were applied to 110 determine the variations in MDR-microbial populations between MDR patient samples 111 (collected from 2021, 2022, and 2023 at SUHRC, Pune) used in this study.

## <sup>112</sup>**3. Results**

## <sup>113</sup>*3.1. Overview of patient infection across all the samples*

<sup>114</sup>One hundred patients aged one day to 98 years were included (data not shown). Eighty-five 115 patients (out of 100 patients) were treated successfully and discharged (Table 1, data not <sup>116</sup>shown), five patients (out of 100 patients) died (**Table 1**) in the hospital, and there was no 117 clarity in the reporting of 10 patients' data whether they discharged or died. Fifty-three 118 patients (53 %), 38 patients (38 %), and nine patients (9 %) were male, female, and child <sup>119</sup>(female), respectively (**Table 1, Fig. S1**) with various clinical characteristics (data not shown

<sup>120</sup>**and Table 1)**. An overall lowest death rate of males were observed among patients (**Fig. 1A**). 121 Patients with comorbidities or with no comorbidities are shown in Table 1. 18 patients with <sup>122</sup>no co-existing comorbidities were observed (**Table 1** and data not shown). The medical 123 conditions at presentation or during the hospital study included; UTI (urinary tract infection, <sup>124</sup>35 % patient), sepsis (16 % patient), foot gangrene (3 % patient), respiratory disease (2 % 125 patient), cancer (1 % patient), hepatic disease (1 % patient), hepatic cyst (1 % patient), 126 asthma (1 % patient), IHD (ischemic heart disease, 1 % patient), CKD (chronic kidney <sup>127</sup>disease,1 % patient), septic shock (1 % patient), post-CAR (chimeric antigen receptors, 1 % 128 patient) T-cell therapy, hyperthyroidism (1 % patient), osteoporosis (1 % patient), 129 hemoperitoneum (1 % patient), multiple vessel (1 % patient), HIE (hypoxic-ischemic 130 encephalopathy, 1 % patient), femur fracture (1 % patient), that were simultaneously present <sup>131</sup>in a patient (**Table 1**). **Table 2** revealed the sample type distribution and predominance of <sup>132</sup>MDR-gram-negative bacteria (MGNB). The sample urine from the patient showed the 133 highest number (61) of MGNB (**Table 2**). In comparison the lowest number (2) of MGNB <sup>134</sup>was present in stool samples (**Table 2**). In terms of bacterial species identified in the samples, <sup>135</sup>MDR-*Klebsiella pneumoniae* was predominant in urine samples (**Table 2**).

# <sup>136</sup>*3.2. Evaluation of antibiotic resistance*

To evaluate antibiotic resistance, an antimicrobial susceptibility test (AST) was performed (**Table S1**). The AST of five GNBs, *Klebsiella pneumoniae* (*K*. *pneumoniae*), followed by *Escherichia coli* (*E*. *coli*), *Citrobacter* sp., *Pseudomonas aeruginosa* (*P*. *aeruginosa*), and *Acinetobacter* sp., were determined during our investigation (**Table S1**). Thirty-one 141 antibiotics were used for susceptibility tests to reveal the MDR characteristics of GNBs isolated from patients. All five GNBs (*K*. *pneumoniae*, *E*. *coli*, *Citrobacter* sp., *P*. *aeruginosa*, and *Acinetobacter* sp.) showed the highest (100 %) resistance to ampicillin, ceftazidime, and ertapenem (**Table S1**). *K*. *pneumoniae*, *E*. *coli*, *P*. *aeruginosa*, and *Acinetobacter* sp. were

ampicillin/sulbactum-resistant (100 %) (**Table S1**). *K*. *pneumoniae*, *E*. *coli*, *Citrobacter* sp., and *P*. *aeruginosa* were aztreonam-resistant (100 %) (**Table S1**). *K*. *pneumoniae*, *E*. *coli*, *Citrobacter* sp., and *Acinetobacter* sp. were ceftriaxone- and cefuroxime-resistant (100 %) (**Table S1**). *K*. *pneumoniae*, *Citrobacter* sp., and *Acinetobacter* sp. were cefotaxime- and cefixime-resistant (100 %) (**Table S1**). *Citrobacter* sp., *P*. *aeruginosa*, and *Acinetobacter* sp. were cotrimoxazole-, meropenem-, and gentamicin-resistant (100 %) (**Table S1**). *E*. *coli*, *P*. *aeruginosa*, and *Acinetobacter* sp. were ciprofloxacin-resistant (100 %) (**Table S1**). *Citrobacter* sp. and *Acinetobacter* sp. were amikacin-, cefepime-, and tobramycin-resistant (100 %) (**Table S1**). *E*. *coli* and *Citrobacter* sp. were ceftazidime avibactam-resistant (100 %) (**Table S1**). *K*. *pneumoniae* and *E*. *coli* were cefazolin-, norfloxacin-resistant (100 %) (**Table S1**). *K*. *pneumoniae* and *Acinetobacter* sp. were imipenem-, nitrofurantoin-, and piperacillin tazobactam-resistant (100 %) (**Table S1**). *Acinetobacter* sp. was amoxicillin 157 clavulanic acid-, ceftazidime clavulanic acid-, cefoxitin-, and minocycline-resistant (100 %) (**Table S1**). *E*. *coli* was doripenem-resistant (100 %) (**Table S1**). Further, *E*. *coli* was 159 tigecycline- and tetracycline-susceptible (100 %) (**Table S1**).

*3.3. Identification of MGNB across all the samples* 

A total of 100 MGNBs belonging to c\_Gammaproteobacteria, were identified across all the 162 samples. 28 %, 56 %, and 16 % MGNB were observed in 2021, 2022, and the early part of 2023, respectively (**Fig. 1B**). Further, in the year 2021, 14 adult males, 11 adult females, and 3 children (female) were infected with MGNB, while in the year 2022, 29 adult males, 23 165 adult females, and 4 children (female) were found to be diseased with MGNB (Fig. 1C). Furthermore, in 2023, 10 adult males, 4 adult females, and 2 children (female) were infected 167 with MGNB (Fig. 1C). The highest number of adult males, adult female, and children (female) patients with MGNB was revealed in the year 2022 (**Fig. 1C**), while the lowest

169 number of adult male, adult female, and children (female) patients with MGNB were 170 observed in the year  $2023$  (**Fig. 1C**).

171 In 100 MGNB isolates, Pseudomonadota was noticed as the dominant phylum among 172 the patient samples. Pseudomonadota alone shared 28, 56, and 16 of the total MGNB isolates <sup>173</sup>in the patient samples collected in 2021, 2022, and 2023, respectively (**Fig. 1B**). The <sup>174</sup>dominant MGNB isolates belonging to Gammaproteobacteria among the patient samples <sup>175</sup>(**Fig. 1D**) depiced the genera *E*. *coli* (28 % isolates), *Citrobacter* sp. (19 % isolates), *K*. <sup>176</sup>*pneumoniae* (40 % isolates), *P*. *aeruginosa* (7 % isolates), and *Acinetobacter* sp. (7 % 177 isolates) (**Fig. S2**).

<sup>178</sup>*3.4. Specific and shared MGNB population* 

179 The number of distinct and shared MGNB isolates present in the patient samples were examined applying a Venn diagram (http://bioinformatics.psb.ugent.be/cgi-bin/liste/Venn/calculate\_venn.htpl) (**Fig. 1E**, **Table S2**). Five shared MGNB populations were 182 identified across all samples. *E. coli*, *K. pneumoniae*, and *Citrobacter* sp. were shared between three patient samples (2021, 2022, and 2023), while *P*. *aeruginosa* and *Acinetobacter* sp. were shared between only two patient (2021 and 2022) and (2022 and 2023) samples, respectively (**Fig. 1E**, **Table S2**).

<sup>186</sup>*3.5. Identification of MGNB in patient (with comorbid) samples* 

<sup>187</sup>*K*. *pneumoniae*, *E*. *coli*, and *Citrobacter* sp. were present in the patient (with comorbid <sup>188</sup>medical conditions) samples collected in 2021 (**Fig. S3A**). *E*. *coli* (in UTI) was highest 189 among the patient (with comorbid) samples (**Fig. S3A**), while *E*. *coli* (in sepsis and hepatic <sup>190</sup>cyst), *K*. *pneumoniae* (in foot gangrene, respiratory disease, and Asthma), *Citrobacter* sp. (in 191 femur fracture) were noted lowest in the patient (with comorbid) samples (**Fig. S3A**).

*K*. *pneumoniae*, *E*. *coli*, *P*. *aeruginosa*, *Citrobacter* sp., and *Acinetobacter* sp. were 193 identified in patient (with comorbid medical conditions) samples collected in 2022 (**Fig. S3B**). *K*. *pneumoniae* (in UTI) was highest among the patient (with comorbid) samples (**Fig. S3B**) while *E*. *coli* (in sepsis, septic shock, cancer, and hemoperitonen), *Citrobacter* sp. (in sepsis, post-CAR, and osteoporosis), *K*. *pneumoniae* (in foot gangrene, respiratory disease, IHD, CKD, hepatic disease, hyperthyroidism) and *P*. *aeruginosa* (in foot gangrene) had the 198 lowest representation in patient (with comorbid) samples (**Fig. S3B**).

<sup>199</sup>*K*. *pneumoniae*, *E*. *coli*, *Citrobacter* sp., and *Acinetobacter* sp. were observed in the 200 patient (with comorbid medical conditions) samples collected in 2023 (Fig. S3C). *E. coli* (in <sup>201</sup>UTI) was highest among the patient (with comorbid) samples (**Fig. S3C**), while *K*. <sup>202</sup>*pneumoniae* (in sepsis and multiple vessels), *Acinetobacter* sp. (in UTI and in HIE) had the 203 lowest representation in the patient (with comorbid) samples (**Fig. S3C**).

# <sup>204</sup>*3.6. Variance indices*

205 Normal distribution, alpha and beta-diversity (taxonomic variance) of the MGNB population 206 was determined utilizing data from various patient' samples. The Shapiro-Wilk (S-W) and <sup>207</sup>Anderson-Darling (A-D) normality test were used to determine distributions of MGNB 208 community within the patient samples. (**Table S3**). The S-W analysis for normality varied <sup>209</sup>from 0.800 to 0.888, with a *P-value* of 0.081 to 0.351. The observed A-D normal distribution <sup>210</sup>differed from 0.343 to 0.511, with a *P-value* of 0.098 to 0.315 (**Table S3**). The Alpha (α)- 211 diversity metrics (Shannon, Simpson, Evenness, Brillouin, Fisher alpha, Chao1, and ACE) of 212 the MGNB population were differed notably within the patient samples (**Table 3**). The values 213 of Shannon diversity (1.138 to 1.508), Simpson diversity (0.643 to 0.775), Evenness diversity <sup>214</sup>(0.780 to 1.042), and Brillouin diversity **(**0.933 to 1.340) (**Table 3**) revealed community 215 structure with moderate species richness and abundance in patient samples. The values of

<sup>216</sup>Fisher alpha and Chao1 ranged from 1.277 to 1.712 and 4 to 5, respectively (**Table 3**). The <sup>217</sup>ACE (abundance-based coverage estimator; a species richness index) varied from 4.000 to <sup>218</sup>5.111, with the increase index in MDR bacteria in 2021 among the patient samples (**Table 3**). 219 Notably, the MDRs in the sample (2022) had more MGNB population than the other samples <sup>220</sup>(**Table 3**). Palaeontological Statistics (PAST, v3) software package was applied to determine 221 the beta  $(\beta)$  diversity of the MGNB population between the patient samples (**Fig. 2A**) 222 collected in 2021, 2022, and 2023. PCoA (principal coordinate analysis, based on the Bray-<sup>223</sup>Kurtis index) was computed using eigenvalues and eigenvectors (coordinates) algorithm from <sup>224</sup>Davis (1986). Before Eigen investigation, PCoA eigen values were produced to the 225 transformation exponent (the power of C), and the definitive index was  $C = 2$ . The "Eigen 226 value scaling" measure was applied for each axis, applying the square root of the eigen 227 matrix (value), and the minimum spanning tree preference was based on the picked PCoA 228 matrix. PCoA revealed the existence or absence of MGNB elements between the patient <sup>229</sup>(2021, 2022, and 2023) samples (**Fig. 2A**). Further, analysis of the data, of pair-wise patient 230 sample, comparisons was determined by applying the Bray-Kurtis similarity and dissimilarity 231 index (**Table S4**). Bray-Kurtis pairwise similarity and distance index of the patient samples 232 varied from 0.444 - 1.000 (Table S4). Moreover, the Whittaker indexes for the resemblance <sup>233</sup>between MGNB population of the patient samples ranged from 0.11 - 0.25 (**Table** S**5**).

<sup>234</sup>*3.7. Comparison of MGNB populations between de Souza GHA et al. (2023), Ruegsegger et*  <sup>235</sup>*al. (2022), and in the present study* 

236 In an effort to understand and correlate the MGNB populations of the present study bacterial 237 communities with that present in the study of de Souza GHA et al. (2023), and Ruegsegger et <sup>238</sup>al. (2022) (**Fig. 2B**, **Table 4**). *Pseudomonas* sp. and *Klebsiell* sp. were revealed at 6.0 and <sup>239</sup>40.0 %, respectively, in the present study, while in the de Souza GHA et al. (2023), they were <sup>240</sup>noted at 11.4 and 40.0 % (**Fig. 2B**, **Table 4**). Further, *E*. *coli* and *Citrobacter* sp. were

241 observed at 28.0 and 19.0 %, respectively in the present study, while in the de Souza GHA et <sup>242</sup>al. (2023) they were noted at 2.8 and 2.8 % (**Fig. 2B**, **Table 4**). Furthermore, *Acinetobacter* 243 sp. was present at 7.0 % in the present study, while in the de Souza GHA et al. (2023) they <sup>244</sup>were revealed at 20.0 % (**Fig. 2B**, **Table 4**).

<sup>245</sup>*Pseudomonas* sp. and *Klebsiella* sp. were present at 6.0 and 40.0 %, respectively, in the 246 present study, while Ruegsegger et al. (2023), reported 34.0 and 14.0 %, respectively (**Fig.**  $\overline{\phantom{a}}$ <sup>247</sup>**2B**, **Table 4**). Further, *E*. *coli* and *Citrobacter* sp. were present at 28.0 and 19.0 %, 248 respectively, in the present study, while Ruegsegger et al. (2023) reported 7.0 and 7.0 %, <sup>249</sup>respectively (**Fig. 2B**, **Table 4**). Furthermore, *Acinetobacter* sp. was present at 7.0 %, in the 250 present study, while in the Ruegsegger et al. (2023) study, they were not reported (Fig. 2B, <sup>251</sup>**Table 4**).

#### <sup>252</sup>**4. Discussion**

<sup>253</sup>GNB are an important public health issue globally due to their antibiotic resistance 254 characteristic (Oliveira and Reygaert, 2022). The invasion of the host by bacteria and the <sup>255</sup>resulting infection is a versatile mechanism that includes various biological factors, i.e. the 256 host defense mechanism, the prevalence and antibiotic susceptibility pattern of microbial 257 isolates, various bio-physicochemical and genetic attributes (Peterson, 1996). The various 258 virulence factors (persistence, transmissibility (ratio of output to input), cling to host cells, 259 host cells invasion, toxigenicity, and the capability to elude or live the host's defence <sup>260</sup>mechanism) of bacteria have been extensively investigated and have shown to have a 261 negative impact on patient's health, particularly when a patient is immunocompromised due 262 to severe disease (Freeman et al., 2020; Moradi et al., 2021). Moreover, it would be valuable 263 to investigate whether patient genotypes can influence survival by influencing the number of 264 MGNB within them (increased or decreased count of MGNB).

<sup>265</sup>ICU-MDR percentages are maximum than in other hospital wards (**Table 1**) due to the <sup>266</sup>multiple associations between the patient's underlying medical conditions, hospital ward 267 type, LOS (length of stay), and employment of various invasive tools (Erbay et al., 2003; 268 Inweregbu et al., 2005; Vincent et al., 2009).

<sup>269</sup>Among the 100 patients investigated, 85 (85 %) were discharged, while 5 (5 %) expired in 270 the hospital (**Fig. 1A**). An overall lower mortality rate was found among elderly, severe 271 patients (with comorbidities) admitted to the different units of the hospital. Our outcomes are 272 not in concurrence with the investigations of Juliana et al. (2022) and Boorgula et al. (2022), <sup>273</sup>who revealed a higher death rate in serious patients. Taking this observation into 274 consideration, we speculate that the lower mortality rate, in our study, might be due to the 275 higher immunity of studied patients during their hospitalization (Parohan et al., 2020; Weiss 276 and Murdoch, 2020; Ejaz et al., 2020). However, such intrinsic protective factors have yet to 277 be determined in specific populations to make the above claims regarding mortality.

<sup>278</sup>In our investigation, *K*. *pneumoniae*, *E*. *coli*, *Citrobacter* sp., *Acinetobacter* sp., *P*. <sup>279</sup>*aeruginosa* were the most frequent isolates (GNB) in various patient' samples (Vijay et al., 280 2021; Sharifipour et al., 2020). GNB isolates were higher in adult males than in adult females 281 and children (female) (**Fig. 1C**). With this observation in view, we hypothesize that a higher 282 level of an enzyme called carboxypeptidase (ACE 2, angiotensin-converting enzyme 2) in <sup>283</sup>men and the predisposition of adult females (at reproductive age) to autoimmune disorder 284 than infectious diseases might be the two reasons for higher MDR-GNB male than in female. <sup>285</sup>Lifestyles of men (heavy smoking and drinking) make them more susceptible to infections 286 (Ramírez-Soto et al., 2021; Bwire, 2020). Nevertheless, this is yet to be elucidated.

<sup>287</sup>Regarding AST, we revealed *Acinetobacter* sp. to be the most (100 %) resistant strain when <sup>288</sup>measured against twenty antibiotics (**Table S1**), while *Klebsiella* sp., was found to be 100 %

<sup>289</sup>resistant against eleven antibiotics (**Table S1**). All these five different bacterial species (**Table**  290 **S1**) were resistant to numerous antimicrobial agents, which gives them the title of multidrug-291 resistant bacteria (Giannitsioti et al., 2022). Surprisingly antibacterial resistance, in this study, 292 is related to a decrease in the mortality rate compared with the previous study (Tanwar et al., 293 2014).

<sup>294</sup>Our data provides evidence of an increase in antimicrobial resistance post-Covid-19 (**Fig. 1C**, 295 data collected in 2022). This is in keeping with previous reports that have mentioned a similar 296 pattern of increased antimicrobial resistance in specific locations (Shomuyiwa et al., 2022). 297 Indiscriminate and irrational antimicrobial use and weak antimicrobials regulatory ecosystem, 298 which could be partially attributed to health systems disruption by inadequate access to health 299 services during the Covid-19 pandemic, are suggested causes for the rapid growth of 300 antimicrobial resistance in the community (Lobie et al., 2021; Shomuyiwa et al., 2022). 301 Given the rapid increase in antimicrobial resistance post-Covid-19 in our study, it is <sup>302</sup>important to further analyze how the policies adopted to manage Covid-19 (i.e. widespread <sup>303</sup>antibiotic and disinfectant usage) affect or have a long-lasting consequence on 304 antimicrobial resistance (AMR) (Nieuwlaat et al., 2021). Furthermore, programs at a <sup>305</sup>governmental level need to be adopted widely, particularly in low- and middle-income 306 countries (LMIC), to contain the possible increase in AMR (Lucien et al., 2021).

### <sup>307</sup>**5. Conclusion**

In conclusion, outcomes achieved from the present investigation revealed that MDR-microbes present in patients are predominantly elements of the gamma-proteobacteria. Antibacterial resistance has an important impact on therapeutics and the outcome of bacterial infection. In this study, five gram-negative bacteria, *K*. *pneumoniae*, *E*. *coli*, *Citrobacter* sp., *Acinetobacter* sp., and *P*. *aeruginosa*, had increased resistance to the antibacterial agents



#### <sup>317</sup>**Declarations**

- <sup>318</sup>**Ethics approval and consent to participate**
- 319 Patient samples and data were collected from the Symbiosis University Hospital and
- <sup>320</sup>Research Centre (SUHRC), the Symbiosis International University, Pune, Maharashtra, India.

## <sup>321</sup>**Consent to publish**

322 Not applicable.

# <sup>323</sup>**Availability of data and materials**

- <sup>324</sup>All data is given in the main body of the manuscript; materials are available from the authors.
- <sup>325</sup>All sequence data is added to manuscript as supplementary files (named as Figure S1 to S3,
- 326 and Tables S1 to S6).

#### <sup>327</sup>**Competing interests**

- 328 The authors declare that they have no competing interests.
- <sup>329</sup>**Funding**
- 330 No funds were used for this study.

# <sup>331</sup>**Authors' contributions**

<sup>332</sup>A.O. made substantial contributions to conception, was involved in analysis & interpretation

- 333 of data, writing, revising and drafting the manuscript, and given final approval of the version
- 334 to be published. D.W. made substantial contributions to writing discussion, editing the



<sup>344</sup>University Hospital and Research Centre (SUHRC), Pune for kind support.

<sup>345</sup>**References**

- <sup>346</sup>1. Alós, J.I., 2015. Resistencia bacteriana a los antibióticos: una crisis global <sup>347</sup>[Antibiotic resistance: A global crisis]. Enferm Infecc Microbiol Clin. 33(10), <sup>348</sup>692-699. https://doi.org/10.1016/j.eimc.2014.10.004. PMID 25475657.
- <sup>349</sup>2. Hernando-Amado, S., Coque, T.M., Baquero, F., Martínez, J.L., 2019. Defining 350 and combating antibiotic resistance from one health and global health 351 perspectives. Nat Microbiol. 4(9), 1432-1442. https://doi.org/10.1038/s41564-352 019-0503-9.
- <sup>353</sup>3. Klein, E.Y., Van Boeckel, T.P., Martinez, E.M., Pant, S., Gandra, S., Levin, S.A., <sup>354</sup>Goossens, H., Laxminarayan, R., 2018. Global increase and geographic <sup>355</sup>convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad 356 Sci USA. 115(15), E3463-E3470. https://doi.org/10.1073/pnas.1717295115.



![](_page_16_Picture_150.jpeg)

- <sup>383</sup>2009. An epidemiological survey of TYLCD in southern Sardinia (Italy). <sup>384</sup>Commun Agric Appl Biol Sci. 74(3), 831-841. PMID 20222569.
- <sup>385</sup>10. Jindal, A.K., Pandya, K., Khan, I.D., 2015. Antimicrobial resistance: a public 386 health challenge. Med J Armed Forces India. 71(2), 178-181. <sup>387</sup>https://doi.org/10.1016/j.mjafi.2014.04.011.
- <sup>388</sup>11. Dogru, A., Sargin, F., Celik, M., Sagiroglu, A.E., Goksel, M.M., Sayhan, H., 2010. <sup>389</sup>The rate of device-associated nosocomial infections in a medical surgical 390 intensive care unit of a training and research hospital in Turkey: one-year 391 outcomes. Jpn J Infect Dis. 63(2), 95-98. PMID 20332569.
- 392 12. Teng, S.O., Lee, W.S., Ou, T.Y., Hsieh, Y.C., Lee, W.C., Lin, Y.C., 2009. Bacterial <sup>393</sup>contamination of patients' medical charts in a surgical ward and the intensive care 394 unit: impact on nosocomial infections. J Microbiol Immunol Infect. 42(1), 86-91. 395 PMID 19424563.
- <sup>396</sup>13. Dettenkofer, M., Ebner, W., Els, T., Babikir, R., Lucking, C., Pelz, K., Rüden, H., 397 Daschner, F., 2001. Surveillance of nosocomial infections in a neurology intensive 398 care unit. J Neurol. 248(11), 959-964. https://doi.org/10.1007/s004150170048.
- <sup>399</sup>14. Ylipalosaari, P., Ala-Kokko, T.I., Laurila, J., Ohtonen, P., Syrjälä, H., 2006. 400 Intensive care acquired infection is an independent risk factor for hospital 401 mortality: a prospective cohort study. Crit Care. 10(2), R66. 402 https://doi.org/10.1186/cc4902.
- 403 15. Weinstein, R.A., 1998. Nosocomial infection update. Emerg Infect Dis. 4(3), 416-<sup>404</sup>420. https://doi.org/10.3201/eid0403.980320.
- <sup>405</sup>16. Iskandar, K., Roques, C., Hallit, S., Husni-Samaha, R., Dirani, N., Rizk, R., Abdo, <sup>406</sup>R., Yared, Y., Matta, M., Mostafa, I., Matta, R., Salameh, P., Molinier, L., 2021.

- <sup>407</sup>The healthcare costs of antimicrobial resistance in Lebanon: a multi-centre 408 prospective cohort study from the payer perspective. BMC Infect Dis. 21(1), 404. <sup>409</sup>https://doi.org/10.1186/s12879-021-06084-w.
- 410 17. Neidell, M.J., Cohen, B., Furuya, Y., Hill, J., Jeon, C.Y., Glied, S., Larson, E.L., <sup>411</sup>2012. Costs of healthcare- and community-associated infections with <sup>412</sup>antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect

**413** Dis. 55(6), 807-815. https://doi.org/10.1093/cid/cis552.

- <sup>414</sup>18. Montassier, E., Batard, E., Gastinne, T., Potel, G., de La Cochetière, M.F., 2013. <sup>415</sup>Recent changes in bacteremia in patients with cancer: a systematic review of 416 epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 32(7), 417 841-850. https://doi.org/10.1007/s10096-013-1819-7.
- 418 19. Gastmeier, P., Sohr, D., Geffers, C., Behnke, M., Daschner, F., Rüden, H., 2005. <sup>419</sup>Mortality risk factors with nosocomial *Staphylococcus aureus* infections in 420 intensive care units: results from the German nosocomial infection surveillance <sup>421</sup>system (KISS). Infection. 33(2), 50-55. https://doi.org/10.1007/s15010-005-3186-  $422$  5.
- 423 20. Horan, T.C., Andrus, M., Dudeck, M.A., 2008. CDC/NHSN surveillance <sup>424</sup>definition of health care-associated infection and criteria for specific types of 425 infections in the acute care setting. Am J Infect Control. 36(5), 309-332. <sup>426</sup>https://doi.org/10.1016/j.ajic.2008.03.002. Erratum in: Am J Infect Control. 36(9), 427 655. PMID 18538699.
- <sup>428</sup>21. Clinical and Laboratory Standards Institute, 2006. Performance standards for <sup>429</sup>antimicrobial susceptibility testing. 13th Informational Supplement, Vol. 25, No. 430 26. Approved Standard M2-A7. Wayne, PA: CLSI.

- 22. Carroll, K.C., Glanz, B.D., Borek, A.P., Burger, C., Bhally, H.S., Henciak, S.,
- Flayhart, D., 2006. Evaluation of the BD phoenix automated microbiology system
- for identification and antimicrobial susceptibility testing of Enterobacteriaceae. J
- Clin Microbiol. 44(10), 3506-3509. https://doi.org/10.1128/JCM.00994-06.
- 23. Hudzicki, J., 2009. Kirby-Bauer disk diffusion susceptibility test protocol. 436 American Society for Microbiology.
- 437 24. Davis, J.C., 1986. Statistics and Data Analysis in Geology. John Wiley & Sons.
- 25. de Souza, G.H.A., de Oliveira, A.R., Dos Santos Barbosa, M., Rossato, L., da 439 Silva Barbosa, K., Simionatto, S., 2023. Multidrug-resistant gram-negative bacteria in patients with COVID-19: an epidemiological and clinical study. J **Infect Public Health. 16(8), 1184-1192.** https://doi.org/10.1016/j.jiph.2023.05.017.
- 26. Ruegsegger, L., Xiao, J., Naziripour, A., Kanumuambidi, T., Brown, D., Williams,
- F., Marshall, S.H., Rudin, S.D., Yen, K., Chu, T., Chen, L., Sozzi, E., Bartelt, L., Kreiswirth, B., Bonomo, R.A., van Duin, D., 2022. Multidrug-resistant gram-negative bacteria in burn patients. Antimicrob Agents Chemother. 66(9), e0068822. https://doi.org/10.1128/aac.00688-22.
- 27. Oliveira, J., Reygaert, W.C., 2022. Gram-negative bacteria. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 30855801.
- 28. Peterson, J.W., 1996. Bacterial pathogenesis. In: Baron S, editor. Medical Microbiology. 4th ed. Galveston (TX): University of Texas Medical Branch at 451 Galveston. Chapter 7. PMID 21413346.
- 29. Freeman, A.M., Leigh, T.R., 2020. JrViral Pneumonia. In: *StatPearls*. StatPearls 453 Publishing. Treasure Island (FL) PMID 30020658.
- 30. Moradi, N., Kazemi, N., Ghaemi, M., Mirzaei, B., 2021. Frequency and antimicrobial resistance pattern of bacterial isolates from patients with COVID-19

![](_page_19_Picture_148.jpeg)

<sup>458</sup>31. Erbay, H., Yalcin, A.N., Serin, S., Turgut, H., Tomatir, E., Cetin, B., Zencir, M., <sup>459</sup>2003. Nosocomial infections in intensive care unit in a Turkish university hospital: 460 a 2-year survey. Intensive Care Med. 29(9), 1482-1488.

461 https://doi.org/10.1007/s00134-003-1788-x.

- 462 32. Inweregbu, K., and others., 2005. Nosocomial infections, continuing education in 463 anaesthesia critical care & pain. 5(1), 14-<sup>464</sup>17, https://doi.org/10.1093/bjaceaccp/mki006.
- <sup>465</sup>33. Vincent, J.L., Rello, J., Marshall, J., Silva, E., Anzueto, A., Martin, C.D., Moreno, <sup>466</sup>R., Lipman, J., Gomersall, C., Sakr, Y., Reinhart, K., 2009. EPIC II group of <sup>467</sup>investigators. International study of the prevalence and outcomes of infection in 468 intensive care units. JAMA. 302(21), 2323-2329. 469 https://doi.org/10.1001/jama.2009.1754.
- <sup>470</sup>34. Juliana, A., Ramya, S., Leela, K.V., 2022. Prevalence and antimicrobial 471 susceptibility pattern of secondary gram-negative bacteria isolated from severe 472 acute respiratory syndrome coronavirus disease 2 patients in a tertiary care <sup>473</sup>hospital. J Pure Appl Microbiol*.* 16(4), 2514-2520. 474 https://doi.org/10.22207/JPAM.16.4.13.
- <sup>475</sup>35. Boorgula, S.Y., Yelamanchili, S., Kottapalli, P., Naga, M.D., 2022. An update on <sup>476</sup>secondary bacterial and fungal infections and their antimicrobial resistance pattern 477 (AMR) in Covid-19 confirmed patients. J Lab Physicians. 14(3), 260-264. 478 https://doi.org/10.1055/s-0041-1741438.
- <sup>479</sup>36. Parohan, M., Yaghoubi, S., Seraji, A., Javanbakht, M.H., Sarraf, P., Djalali, M., 480 2020. Risk factors for mortality in patients with coronavirus disease 2019 (Covid-

![](_page_20_Picture_148.jpeg)

- Covid-19. Lancet. 395(10229), 1014-1015. https://doi.org/10.1016/S0140- 485 6736(20)30633-4.
- 38. Ejaz, H., Alsrhani, A., Zafar, A., Javed, H., Junaid, K., Abdalla, A.E., Abosalif, K.O.A., Ahmed, Z., Younas, S., 2020. Covid-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 13(12), 1833-1839. 489 https://doi.org/10.1016/j.jiph.2020.07.014.
- 39. Vijay, S., Bansal, N., Rao, B.K., Veeraraghavan, B., Rodrigues, C., Wattal, C.,
- Goyal, J.P., Tadepalli, K., Mathur, P., Venkateswaran, R., Venkatasubramanian, R.,
- Khadanga, S., Bhattacharya, S., Mukherjee, S., Baveja, S., Sistla, S., Panda, S., Walia, K., 2021. Secondary infections in hospitalized Covid-19 patients: Indian 494 experience. Infect Drug Resist. 14, 1893-1903.
- 495 https://doi.org/10.2147/IDR.S299774.
- 40. Sharifipour, E., Shams, S., Esmkhani, M., Khodadadi, J., Fotouhi-Ardakani, R., Koohpaei, A., Doosti, Z., Ej Golzari, S., 2020. Evaluation of bacterial co-infections of the respiratory tract in Covid-19 patients admitted to ICU. BMC **Infect Dis. 20(1), 646.** https://doi.org/10.1186/s12879-020-05374-z.
- 41. Ramírez-Soto, M.C., Arroyo-Hernández, H., Ortega-Cáceres, G., 2021. Sex 501 differences in the incidence, mortality, and fatality of Covid-19 in Peru. PLoS **One. 16(6), e0253193.** https://doi.org/10.1371/journal.pone.0253193.
- 42. Bwire, G.M., 2020. Coronavirus: Why men are more vulnerable to Covid-19 than women? SN Compr Clin Med. 2(7), 874-876. https://doi.org/10.1007/s42399-020- 505 00341-w.

![](_page_21_Picture_144.jpeg)

![](_page_22_Picture_150.jpeg)

- <sup>531</sup>M., Cerpa, M., Joseph, G.A., Maki, G., Zervos, M.J., Dely, P., Boncy, J., Sati, H.,
- <sup>532</sup>Rio, A.D., Ramon-Pardo, P., 2021. Antibiotics and antimicrobial resistance in the
- <sup>533</sup>Covid-19 era: Perspective from resource-limited settings. Int J Infect Dis.104,
- <sup>534</sup>250-254. https://doi.org/10.1016/j.ijid.2020.12.087.

#### <sup>535</sup>**Figure legends**

<sup>536</sup>**Fig. 1** Overview of study. (A) Outcomes of patients with MDR-gram negative bacterial 537 pathogens. (B) Percentage overview of patients with MDR-gram negative bacterial 538 pathogens. (C) Distribution of MDR-gram negative bacterial pathogens in adult male, adult 539 female, and children (female). (D) Relative abundance of different MDR-gram negative <sup>540</sup>bacterial pathogens among all patient samples at the level of genus. (E) Identification of 541 specific and shared MDR-gram negative bacterial pathogens among the patient samples.

<sup>542</sup>**Fig. 2** Principal coordinate analysis and comparative overview of MGNB communities 543 identified in patients. (A) Analysis of MDR-gram negative bacterial pathogens diversity in 544 the patient samples collected in different, 2021, 2022, and 2023, years. MDR-gram negative <sup>545</sup>bacterial pathogens diversity in the patient samples using principal coordinate analysis <sup>546</sup>(PCoA-Bray-Kurtis index). (B) Comparative overview of MDR-gram negative bacterial 547 communities identified in patient samples of the Hospital-acquired infection (in this study), 548 de Souza GHA et al (2023), and Ruegsegger et al (2022).

<sup>549</sup>**Table legends** 

<sup>550</sup>**Table 1** Representation and clinical traits in patients with hospital-acquired infections (HAI, <sup>551</sup>2021-2023).

<sup>552</sup>**Table 2** Predominance of MDR-gram negative bacterial pathogens from different sample 553 types of patients.

<sup>554</sup>**Table 3** Alpha-diversity indices and the estimated richness of MDR-gram negative bacterial

- 555 population in the patient samples.
- <sup>556</sup>**Table 4** Comparative overview of MDR-gram negative bacterial populations identified in
- 557 patients from investigation of de Souza GHA et al., 2023, Ruegsegger et al., 2022, and in this
- 558 study.

# <sup>559</sup>**Supplementary material**

- <sup>560</sup>**Fig. S1** Overview of MDR-gram negative bacterial pathogens collected from the gender 561 wise patients.
- <sup>562</sup>**Fig. S2** Relative abundance of different MDR-gram negative bacterial pathogens among all 563 patient samples at the level of species.
- <sup>564</sup>**Fig. S3** Description of MDR-gram negative bacterial pathogens among the patient with 565 comorbid condition collected in different, (A) 2021, (B) 2022, and (C) 2023, years from 566 hospital.
- <sup>567</sup>**Table S1** Antimicrobial susceptibility tests. Antimicrobial susceptibility tests of MGNB 568 pathogens collected from patient samples.
- <sup>569</sup>**Table S2** Labeling of specific and shared MGNB communities among the patient samples
- 570 during Covid-19 and post-Covid-19 year. (A) Specific MGNB communities (specific and
- 571 shared) in patient samples. (B) Shared MGNB communities in patient samples.
- <sup>572</sup>**Table S3** Statistics of MGNB collected different years from the patient samples.
- <sup>573</sup>**Table S4** Bray-Kurtis pairwise similarity and distance (dissimilarity) index of MGNB
- 574 population among the patient samples collected in 2021, 2022, and 2023.

- <sup>575</sup>**Table S5** Beta-diversity, Whittaker indexes, and pair-wise comparisons between the patient
- 576 samples based on MGNB populations.

577

- 578
- 579

580

![](_page_25_Figure_0.jpeg)

![](_page_25_Figure_1.jpeg)

![](_page_25_Figure_2.jpeg)

![](_page_25_Figure_3.jpeg)

Fig. 2

![](_page_26_Figure_1.jpeg)

![](_page_27_Picture_161.jpeg)

Table 11 Characteristics of hospital stay of patients with or without comorbidities, 2021-2023 (Covid-19/ or post Covid-19) period.

![](_page_28_Picture_85.jpeg)

 $\mathbf{1}$ 

 $\mathbf{1}$ 

 $\boldsymbol{0}$ 

 $\overline{4}$ 

Table 21 Dominancy of MDR bacterial isolates from different types of patient's sample.

Isolates Sample types

Note# Pus; A thick, whitish-yellow fluid of WBCs (white blood cells), cellular debris, and liquefied tissue. SWAB; a medical device used for the collection of biological samples from the patient body. BAL; Bronchoalveolar lavage, ET; Endotracheal secretion.

*Klebsiella pneumoniae* 7 20 3 2 2 2 3

*Citrobacter* 2 16 0 0 0 0 1

*Pseudomonas aeruginosa* 1 6 0 0 0 0 0 0 0 0

Total 14 61 9 4 2 3 4

*Escherichia coli* 2 18 4 1 0 0 1

*Acinetobacter* 2 1 2 1 0 1

Pus Urine SWAB Sputum Stool BAL ET

![](_page_29_Picture_46.jpeg)

Table 3| Alpha-diversity metrics of MDR bacterial population in the patient samples.

Table 4<sup>1</sup> Comparative synopsis of MDR bacteria observed in present study patient' samples (during Hospital stay), de Souza GHA et al., 2023, and Ruegsegger et al., 2022. (ND; Not determined).

![](_page_30_Picture_56.jpeg)